A clear case of metabolic syndrome...or is it?
Living with lipodystrophy and the urgency to treat
Back in the clinic - an interactive case presentation with Q&A
Prof. David Araújo-Vilar describes the main challenges patients face on their journey to a diagnosis of lipodystrophy, the role of speicalist centres in diagnosis and how diagnosis can be improved.
Prof. Martin Wabitsch provides an overview of the main signs and symptoms of lipodystrophy and which ones are the most difficult to manage, in addition to describing the objectives of treatment and the triggers for re-evaluating management.
Prof. Barış Akıncı outlines the burden of lipodystrophy, why it is important to get symptoms under control urgently and what can be achieved with optimum care.
Please Select A Video:
Overview & Learning Objectives
Lipodystrophy is a heterogeneous group of rare metabolic disorders characterised by the loss of adipose tissue and leptin deficiency. Typical symptoms include insulin resistance, diabetes and hypertriglyceridaemia, which if left untreated, can lead to complications including hepatic steatosis, pancreatitis, and early-onset atherosclerosis can develop.
The information in this activity is intended for healthcare professionals involved in the diagnosis and treatment of patients with lipodystrophy.
Part of this touchSYMPOSIUM HIGHLIGHTS was recorded live during the e-ECE 2020: the 22nd European Congress of Endocrinology in September 2020. The symposium was organised by Amryt Pharmaceuticals DAC.
After watching this activity participants should be better able to:
- Recognise the main signs, symptoms and complications of lipodystrophy and its subtypes
- Understand the main challenges to a diagnoses of lipodystrophy and how a definitive diagnosis is made
- Describe the role of specialist centres in the diagnosis and management of lipodystrophy
- Understand the burden of lipodystrophy and why it is important to initiate treatment quickly to prevent complications
- Demonstrate knowledge of how to effectively manage lipodystrophy and the associated metabolic complications
Adverse reactions should be reported to Amryt Pharmaceuticals DAC by email firstname.lastname@example.org or by telephoning the free phone number: 00800 4447 4447. Adverse reactions can also be reported via the Yellow Card Scheme at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.
- Brown RJ, Araujo-Vilar D, Cheung PT, et al. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab. 2016;101:4500–11.
- Chehab FF. Obesity and lipodystrophy-where do the circles intersect? Endocrinology. 2008;149:92–34.
- Chiquette E, Oral EA, Garg A, et al. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017;10: 375–83.
- Handelsman Y, Oral EA, Bloomgarden ZT, et al. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013;19:107–16.
- Lima JG, Nobrega LH, de Lima NN, et al. Clinical and laboratory data of a large series of patients with congenital generalized lipodystrophy. Diabetol Metab Syndr. 2016; 8:23.
- Krawiec P, Mełges B, Pac-Kożuchowska E, et al. Fitting the pieces of the puzzle together: a case report of the Dunnigan-type of familial partial lipodystrophy in the adolescent girl. BMC Pediatr. 2016;16:38.
- Patni N, Li X, Adams-Huet B, et al. Regional Body Fat Changes and Metabolic Complications in Children With Dunnigan Lipodystrophy-Causing LMNA Variants. J Clin Endocrinol Metab. 2019;104:1099–108.
- Akinci B, Oral EA, Neidert A, et al. Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review Study. J Clin Endocrinol Metab. 2019;104:5120–35.
- Akinci B, Unlu SM, Celik A, et al. Renal complications of lipodystrophy: A closer look at the natural history of kidney disease. Clin Endocrinol (Oxf). 2018;89:65–75.
- Akinci B, Onay H, Demir T, et al. Natural History of Congenital Generalized Lipodystrophy: A Nationwide Study From Turkey. J Clin Endocrinol Metab. 2016;101:2759–67.
- Amryt Pharmaceuticals Myalepta Summary of Product Characteristics; Weblink: https://www.ema.europa.eu/en/documents/product-information/myalepta-epar-product-information_en.pdf(accessed October 2020).
- Brown RJ, Valencia A, Startzell M, et al. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy. J Clin Invest. 2018;128:3504–16.
- Brown RJ, Oral EA, Cochran E, et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Endocrine. 2018;60:479–89.
- Oral EA, Gorden P, Cochran E, et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. Endocrine. 2019;64:500–11.
- Baykal AP, Parks EJ, Shamburek R, et al. Leptin decreases de novo lipogenesis in patients with lipodystrophy. JCI Insight. 2020;5(14).
- Ali. O, Cook. K, Lee. D, et al. Discrete choice and SF-36 estimates of patient quality of life and benefits of leptin replacement therapy (LRT) in generalized and partial lipodystrophy (GL, PL) (P589). European Congress of Endocrinology. Lyon, France; 2019.
- Ali OA, Cook K, Gupta D, et al. Effect of Leptin Replacement Therapy (LRT) on Survival and Disease Progression in Generalized and Partial Lipodystrophy (GL, PL). Diabetes. 2018;67(Supplement 1):106-LB.